Biomarkers have transformed the landscape of modern oncology, offering precise biological information that guides diagnosis, treatment selection, and clinical research. Understanding how these molecular signals function is essential for patients navigating cancer care and considering participation in clinical trials.
Key Takeaways
- A biomarker is a measurable biological indicator that reflects normal or abnormal processes in the body, including disease activity.
- In oncology, biomarkers help classify cancer types, predict treatment response, and monitor disease progression.
- Biomarker testing is increasingly used to determine whether a patient qualifies for a specific clinical trial.
- Personalized cancer treatment depends heavily on matching a patient’s biomarker profile to targeted therapies.
- Common biomarker tests include genetic sequencing, protein assays, and liquid biopsies.
What Is a Biomarker? How Is It Used in Clinical Trials?
Biomarker refers to any measurable biological characteristic that serves as an indicator of a normal biological process, a pathogenic process, or a pharmacological response to a therapeutic intervention. In medicine, biomarkers can be molecules found in blood, tissue, urine, or other bodily fluids — including proteins, genes, hormones, or even imaging features. The U.S. Food and Drug Administration (FDA) defines a biomarker as a defined characteristic that is measured as an indicator of biological processes, pathogenic processes, or responses to an exposure or intervention.
In the context of oncology, biomarkers carry particular significance. A biomarker definition in oncology extends beyond simple measurement: it encompasses molecular alterations in tumor cells that can distinguish one cancer subtype from another, predict how aggressively a cancer will behave, and indicate whether a specific therapy is likely to be effective. For example, the presence of HER2 protein overexpression in breast cancer is a well-established oncologic biomarker that directly informs treatment selection.
Clinical trials rely on biomarkers in multiple ways. Researchers use them as endpoints to measure whether an experimental treatment is working, as safety signals to monitor patient health during a trial, and as selection criteria to identify which patients are most likely to benefit from a given intervention. According to the National Cancer Institute, the integration of biomarker-driven endpoints has significantly improved the efficiency and relevance of oncology trials over the past two decades. By anchoring trial design to biological evidence, investigators can more accurately assess therapeutic value and reduce unnecessary exposure to ineffective treatments.
Types of Biomarkers in Cancer Research and Oncology
The types of biomarkers in cancer research are broad and categorized by their biological function and clinical application. Understanding these categories helps clarify why different patients with the same cancer diagnosis may receive entirely different treatment plans.
| Biomarker Type | Definition | Clinical Application |
|---|---|---|
| Diagnostic | Identifies the presence of a disease | Confirms cancer diagnosis (e.g., PSA for prostate cancer) |
| Prognostic | Predicts disease course regardless of treatment | Estimates likelihood of recurrence or survival |
| Predictive | Forecasts response to a specific treatment | Identifies patients likely to respond to targeted therapy |
| Pharmacodynamic | Measures biological effect of a drug | Confirms the drug is hitting its intended target |
| Surrogate endpoint | Substitutes for a clinical outcome in trials | Tumor shrinkage used as a proxy for survival benefit |
Genomic biomarkers represent one of the most rapidly advancing categories. These include specific gene mutations, amplifications, or deletions detected through next-generation sequencing (NGS). For instance, EGFR mutations in non-small cell lung cancer and BRCA1/BRCA2 mutations in breast and ovarian cancers are genomic biomarkers that directly inform targeted therapy choices. Protein-based biomarkers, such as PD-L1 expression levels, guide decisions around immunotherapy eligibility.
Liquid biopsies represent an emerging and minimally invasive approach to biomarker testing. By analyzing circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) from a blood sample, oncologists can detect cancer-related genetic changes without requiring surgical tissue extraction. This method is particularly valuable for monitoring treatment response over time and detecting early signs of resistance or recurrence, making it a powerful tool in both routine oncology care and clinical trial monitoring.
How Biomarker Testing Determines Clinical Trial Eligibility
The role of biomarkers in clinical trial eligibility has grown substantially as precision oncology has advanced. Modern clinical trials — particularly those evaluating targeted therapies or immunotherapies — often require patients to have a specific biomarker profile before they can enroll. This approach, known as biomarker-selected or enrichment trial design, ensures that the experimental treatment is tested in the population most likely to respond.
When a patient’s tumor is tested, results can reveal whether they carry actionable alterations — genetic or molecular changes that match the mechanism of an investigational drug. For example, a trial testing a KRAS G12C inhibitor would require confirmed KRAS G12C mutation status as an eligibility criterion. Without the relevant biomarker, a patient would not meet the inclusion criteria, regardless of their cancer stage or overall health status. Conversely, the presence of the required biomarker may open access to a cutting-edge treatment that would otherwise be unavailable outside the trial setting.
Comprehensive biomarker testing — including broad molecular profiling — is increasingly recommended at the time of diagnosis or disease progression to maximize a patient’s chances of qualifying for relevant trials. A 2020 analysis published in Nature Medicine found that patients whose tumors underwent comprehensive genomic profiling were significantly more likely to be matched to a biomarker-driven clinical trial than those who received limited testing. This finding underscores the importance of thorough molecular workup as a standard step in oncology care.
- Biomarker results can confirm eligibility or disqualification for specific trials.
- Some trials require testing for multiple biomarkers simultaneously using panel-based assays.
- Liquid biopsy results may complement or supplement tumor tissue testing in eligibility determinations.
- Patients should discuss comprehensive genomic profiling with their oncologist early in their diagnosis.
It is also worth noting that biomarker data collected during a trial contributes to broader scientific knowledge. Researchers use this data to refine future trial designs, identify new therapeutic targets, and better understand mechanisms of resistance — creating a cycle of evidence that benefits future patients.
Biomarkers and Personalized Cancer Treatment Decisions
Biomarkers and personalized cancer treatment are deeply interconnected. The concept of personalized — or precision — medicine rests on the principle that cancer is not a single disease but a collection of molecularly distinct conditions, each requiring a tailored therapeutic approach. Biomarker testing provides the molecular map that makes this tailored approach possible.
What a biomarker test shows in cancer extends well beyond a simple positive or negative result. A comprehensive biomarker report may reveal tumor mutational burden (TMB), microsatellite instability (MSI) status, specific gene fusions, copy number variations, and expression levels of immune checkpoint proteins. Each of these findings can influence whether a patient receives chemotherapy, targeted therapy, immunotherapy, or a combination — and at what dose or sequence.
The clinical impact of biomarker-guided treatment is well documented. For instance, patients with non-small cell lung cancer harboring ALK gene fusions who receive ALK inhibitors experience significantly better outcomes than those treated with standard chemotherapy. Similarly, colorectal cancer patients with mismatch repair deficiency (dMMR) respond far better to PD-1 inhibitors than those with proficient mismatch repair (pMMR) tumors. These examples illustrate how what is a biomarker in medicine translates directly into clinical decisions with measurable patient benefit.
As biomarker science evolves, new categories of actionable alterations are continuously being identified and validated. Regulatory agencies including the FDA have approved multiple companion diagnostic tests — laboratory tests developed alongside specific drugs — to ensure that biomarker-driven prescribing is both accurate and standardized. Patients are encouraged to ask their care team about biomarker testing options at every stage of their cancer journey, as results can change following disease progression or treatment.
Frequently Asked Questions
Can a patient’s biomarker status change over time?
Yes. Tumors can evolve under treatment pressure, leading to new mutations or loss of previously identified biomarkers — a process known as clonal evolution. This is why repeat biomarker testing at disease progression is often recommended. Updated results may reveal new targetable alterations or explain why a previously effective treatment has stopped working, enabling oncologists to adjust the therapeutic strategy accordingly.
Is biomarker testing covered by insurance for cancer patients?
Coverage varies by country, insurer, and the specific test ordered. In the United States, Medicare and many private insurers cover FDA-approved companion diagnostic tests and, in some cases, broad genomic profiling panels. Patients should verify coverage with their insurance provider before testing. Some clinical trials and cancer centers also offer biomarker testing at no cost as part of their research protocols, which can be an important access pathway.
Are all biomarker tests performed on tumor tissue?
No. While traditional biomarker testing requires a tumor tissue biopsy, liquid biopsy techniques now allow analysis of circulating tumor DNA from a standard blood draw. Liquid biopsies are less invasive and can be repeated more frequently, making them suitable for monitoring treatment response or detecting early recurrence. In some cases, both tissue and liquid biopsy results are used together to build a more complete molecular picture of a patient’s cancer.
